The most complete study of clinical success rates may be even lower than previous estimates. According to a report from Nature Publishing Group, Hay and colleagues conducted a detailed analysis of phase transitions of 4,451 drugs with 7,372 independent clinical development paths from 2003 to 2011. The successful transition rate from Phase I to Phase II was 60% in the period of 1991–2000. Only 32% of the drug successfully made the transition from Phase II to Phase III. On average, the likelihood of reaching FDA approval (LOA) from Phase I was about 10%. Thus, the Contract Research Organizations (CROs) outsourcing services market has witnessed significant growth in the past decade. This growth has been attributed to the rising costs involved in conducting various phases of clinical trials ranging from drug discovery up to post-marketing approvals.
This fall at Partnerships in Clinical Trials Asia, we'll gather a group of experts including Duanghatai Chirapathomsakul, Associate Director Global Clinical Quality Assurance, Lundbeck from Thailand and John Gong, Senior Vice President, Clinical Operations, Beigene of China to participate in the panel discussion Quality Driven Drug Development in the Asia Pacific Region to talk about bringing drugs from discovery and through the clinical trial phases. For more information on this session, download the agenda. If you'd like to meet and network with these panelists this September 22-24 in Shanghai, as a reader of this blog, you can save 20% off the standard rate when you register to join us.